Core Insights - BioCardia, Inc. and CART-Tech, B.V. have entered into an exclusive development and commercialization agreement for Heart3D™ Fusion Imaging, aimed at enhancing cardiac biotherapeutic delivery and biopsy procedures [1][2] - The Heart3D system will fuse two-dimensional x-ray images with three-dimensional anatomical heart models, improving procedural accuracy for interventional cardiologists [4] Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with a focus on biotherapeutic platforms such as CardiAMP and CardiALLO [5] - CART-Tech specializes in vendor-independent platform technology for augmented fluoroscopy during cardiac interventions, with over ten years of experience in the field [6] Partnership Details - The partnership will initially market Heart3D Fusion Imaging as a research tool, with plans for clinical approval in the future [2] - BioCardia will have exclusive distribution rights for biotherapeutic delivery globally and for cardiac biopsy in the U.S., while CART-Tech retains other distribution rights [2] Market Potential - The partnership is projected to generate significant revenue, with estimates suggesting that a single approved biologic therapy could yield $100 million annually from Heart3D services if it becomes standard of care [3]